Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BCG intravesical instillations: recommendations for side-effects management.

P Rischmann1, F Desgrandchamps, B Malavaud

  • 1Urologie, C.H.U. Purpan, Toulouse, France. rischmann.p@chu-toulouse.fr

European Urology
|November 27, 1999
PubMed
Summary

Adverse events from intravesical BCG therapy are common but manageable. While most side effects are mild, severe complications require prompt treatment and may contraindicate further BCG instillations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology.

World journal of urology·2024
Same author

Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection.

The French journal of urology·2023
Same author

[Profile and immune environment of upper tract urothelial carcinoma].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

Significant prostate cancer risk after MRI-guided biopsy showing benign findings: Results from a cohort of 381 men.

The French journal of urology·2023
Same author

Salvage Percutaneous Cryoablation for Bleeding Upper Tract Urothelial Carcinoma.

Cardiovascular and interventional radiology·2022
Same author

Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2022

Area of Science:

  • Oncology
  • Immunology
  • Infectious Diseases

Background:

  • Intravesical Bacillus Calmette-Guérin (BCG) therapy is a standard treatment for non-muscle-invasive bladder cancer.
  • Adverse events associated with BCG therapy can range from mild, transient symptoms to severe, systemic complications.

Purpose of the Study:

  • To review the spectrum of adverse events following intravesical BCG therapy.
  • To outline management strategies for common and severe complications.
  • To discuss the risk-benefit ratio of BCG therapy in bladder cancer treatment.

Main Methods:

  • Literature review of adverse events associated with intravesical BCG therapy.
  • Analysis of reported complications, their incidence, and management protocols.
  • Evaluation of treatment outcomes and contraindications for further BCG administration.

Related Experiment Videos

Main Results:

  • Common side effects include low-grade fever and irritative voiding symptoms, typically resolving within 48 hours.
  • 10-15% of patients experience local or systemic complications, including genitourinary infections, prostatitis, epididymitis, and systemic infections like nephritis or pneumonitis.
  • Severe, life-threatening events such as sepsis or immunoallergic reactions can occur, requiring immediate antitubercular and anti-inflammatory treatment.

Conclusions:

  • Most BCG-related adverse events are manageable with supportive care and dose modification.
  • Severe complications necessitate prompt intervention and may lead to permanent discontinuation of BCG therapy.
  • Despite potential toxicity, intravesical BCG remains a favorable treatment option for moderate- and high-risk bladder tumors due to its efficacy.